September 10th, 2013
Have We Solved The Problem of Ghostwriting?
Harlan M. Krumholz, MD, SM
Several years ago, in the midst of the Vioxx litigation, I became aware of the practice of ghostwriting throughout academic medicine. In general, marketing arms of pharmaceutical companies wanted to seed the peer-reviewed journals with articles published by academics. They would identify an academic and provide him or her drafts of the article. Sometimes they […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?